<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55541">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383095</url>
  </required_header>
  <id_info>
    <org_study_id>5937</org_study_id>
    <nct_id>NCT02383095</nct_id>
  </id_info>
  <brief_title>Art-therapy and Psychotic Disorders</brief_title>
  <official_title>Efficiency of Art-therapy in Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the protocol is to test the efficiency of art-therapy versus
      metacognitive rehabilitation on the visual perception disorders observed in patients with
      schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Response times between baseline and after 16 therapy sessions</measure>
    <time_frame>Baseline and after 16 therapy sessions (up to 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical scales (SAPS and SANS) between baseline and after 16 therapy sessions</measure>
    <time_frame>Baseline and after 16 therapy sessions (up to 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in esthetic perception between baseline and after 16 therapy sessions</measure>
    <time_frame>Baseline and after 16 therapy sessions (up to 6 months)</time_frame>
    <description>Esthetic Perception Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in errors in visual organization tasks between baseline and after 16 therapy sessions</measure>
    <time_frame>aseline and after 16 therapy sessions (up to 6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Art-therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 Art-therapy sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacognitive therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 Metacognitive therapy sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Art therapy</intervention_name>
    <arm_group_label>Art-therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>metacognitive therapy</intervention_name>
    <arm_group_label>Metacognitive therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  schizophrenia according to DSM IV

        Exclusion Criteria:

          -  addiction problem

          -  invalidating visual sensory problems

          -  neurological history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne GIERSCH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne GIERSCH, PhD</last_name>
    <phone>+33388116471</phone>
    <email>giersch@unistra.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de psychiatrie, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne GIERSCH, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 18, 2016</lastchanged_date>
  <firstreceived_date>January 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Art-therapy</keyword>
  <keyword>Visual organization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
